A-Alpha Bio

The company's AlphaSeq platform applies synthetic biology to experimentally measure millions of protein-protein interaction affinities simultaneously.

Protein binding data is incorporated into the company's AlphaBind platform to train machine learning models that predict binding from sequence. A-Alpha Bio uses both platforms to discover and optimize high-impact therapeutics for their own pipeline and in partnership with industry leaders.

A-Alpha Bio is based in Seattle and was founded in 2017 at the University of Washington's Institute for Protein Design and Center for Synthetic Biology.

Latest A-Alpha Bio News & Features